New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four…
Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C) over four years of treatment1,2At…